IITRI announces the recent award of three major new programs by the Biomedical Advanced Research and Development Authority (BARDA) valued at more than $4.7 M. The programs are for the development and/or evaluation of cutting edge technologies and agents to control infectious diseases of critical importance to human health.
These new programs include:
- Development and Qualification of Stocks and Assays for Studies with Zika Virus
- Development of a Novel Model to Evaluate Vaccine Efficacy against Influenza
- Efficacy Studies of Monoclonal Antibodies against Ebola Virus (joint program with Texas Biomedical Research Institute)
Congratulations to Robert Baker, David Boltz, and the entire IITRI team for winning these programs.
Recent Comments